- Abatacept: The risk or severity of adverse effects can be increased when Adalimumab is combined with Abatacept.
- Aminophylline: The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab.
- Anakinra: The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.
- Belimumab: The risk or severity of adverse effects can be increased when Adalimumab is combined with Belimumab.
- Canakinumab: The risk or severity of adverse effects can be increased when Adalimumab is combined with Canakinumab.
- Certolizumab pegol: Adalimumab may increase the immunosuppressive activities of Certolizumab pegol.
- Cyclosporine: The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.
- Denosumab: The risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.
- Infliximab: Adalimumab may increase the immunosuppressive activities of Infliximab.
- Leflunomide: The risk or severity of adverse effects can be increased when Adalimumab is combined with Leflunomide.
- Natalizumab: The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.
- Pimecrolimus: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.
- Rilonacept: The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilonacept.
- Roflumilast: Roflumilast may increase the immunosuppressive activities of Adalimumab.
- Sipuleuce: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab.
- Tacrolimus: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab.
- Theophylline: The serum concentration of Theophylline can be decreased when it is combined with Adalimumab.
- Tocilizumab: Tocilizumab may increase the immunosuppressive activities of Adalimumab.
- Tofacitinib: The risk or severity of adverse effects can be increased when Adalimumab is combined with Tofacitinib.
- Trastuzumab: Trastuzumab may increase the neutropenic activities of Adalimumab.
- Vedolizumab: The risk or severity of adverse effects can be increased when Adalimumab is combined with Vedolizumab.
- Warfarin: The serum concentration of Warfarin can be decreased when it is combined with Adalimumab.
human monoclonal antibody against TNF-alpha (tumor necrosis factor-alpha, cell signaling protein - cytokine - involved in systemic inflammation). Adalimumab is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Trade names: Humira (Abbvie) and Exemptia (biosimalr by Zydus Cadila). Adalimumab has been approved in the United States for rheumatoid arthritis, psoriatic arthritis (psA), ankylosing spondylitis (AS), Crohn's disease, ulcerative colitis, moderate to severe chronic plaque psoriasis (Ps), moderate to severe hidradenitis suppurativa, and juvenile idiopathic arthritis. Drug interactions:
Comments
|
Categories
All
|